100 results on '"Travis, Simon P."'
Search Results
2. 629 A SINGLE-CELL THERAPEUTIC ATLAS OF ANTI-TUMOUR NECROSIS FACTOR THERAPY IN INFLAMMATORY BOWEL DISEASE
3. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
4. Sa1626: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF ULCERATIVE COLITIS SYMPTOMS ON DAILY LIFE
5. 978: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF MODERATELY-TO-SEVERELY-ACTIVE ULCERATIVE COLITIS ON SEXUAL ACTIVITY
6. Sa1624: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: BURDEN AND IMPACT OF BOWEL URGENCY ON PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
7. 584: VEDOLIZUMAB INTRAVENOUS IS EFFECTIVE ACROSS MULTIPLE TREATMENT TARGETS IN CHRONIC POUCHITIS: RESULTS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EARNEST TRIAL
8. 905 DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL
9. Tu1370 IMPROVING ACUTE UPPER GI BLEEDING MANAGEMENT IN THE UNITED KINGDOM: 2022 INSIGHTS VS. 2007 - UNVEILING PATIENT PROFILES, DIAGNOSES, AND OUTCOMES FROM A 5000-PATIENT MULTICENTRE AUDIT
10. 253 REBLEEDING AND MORTALITY IN ACUTE UPPER GASTROINTESTINAL BLEEDING WITH VARICES: INSIGHTS FROM A PROSPECTIVE MULTICENTER STUDY IN UK HOSPITALS
11. Tu1372 MANAGING ACUTE UPPER GASTROINTESTINAL BLEEDING IN ANTICOAGULATED PATIENTS: FINDINGS FROM A LARGE UK MULTICENTER STUDY OF 5000 PATIENTS
12. Su1847 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF MODERATE-TO-SEVERE CROHN'S DISEASE SYMPTOMS ON HEALTH CARE PROFESSIONAL TREATMENT DECISIONS IN THE UNITED STATES AND EUROPE
13. Su1814 CLINICAL RELEVANCE OF BASELINE AND CHANGE IN URGENCY NUMERIC RATING SCALE SCORE FOR MIRIKIZUMAB TREATMENT FOR ULCERATIVE COLITIS
14. Su1866 MIRIKIZUMAB IMPROVES FATIGUE, BOWEL URGENCY, AND QUALITY OF LIFE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM A PHASE 3 CLINICAL TRIAL
15. Su1865 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: EUROPEAN AND US PATIENT AND HEALTH CARE PROFESSIONAL PERSPECTIVES ON THE BROAD IMPACT OF BOWEL URGENCY IN ULCERATIVE COLITIS
16. Su1859 COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: UNITED STATES AND EUROPEAN PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE-TO-SEVERE CROHN'S DISEASE ON SEXUAL ACTIVITY
17. 106 RANDOMIZED CLINICAL TRIAL: EXCLUSIVE ENTERAL NUTRITION VERSUS STANDARD OF CARE FOR ACUTE SEVERE ULCERATIVE COLITIS
18. Tu1747 INTERIM RESULTS FROM THE RANDOMIZED VERDICT TRIAL TO DETERMINE THE OPTIMAL TREATMENT TARGET IN PATIENTS WITH ULCERATIVE COLITIS
19. Mo1867 EXCLUSIVE ENTERAL NUTRITION, THE GUT MICROBIOME AND CORTICOSTEROID RESPONSE IN PATIENTS WITH ACUTE SEVERE COLITIS
20. Sa1151 MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CHRONIC POUCHITIS: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
21. 352 DEVELOPMENT AND VALIDATION OF A NOVEL COMPOSITE INDEX FOR THE ASSESSMENT OF ENDOSCOPIC AND HISTOLOGIC DISEASE ACTIVITY IN POUCHITIS: THE ATLANTIC POUCHITIS INDEX
22. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease
23. Su1931 PATIENT-REPORTED SYMPTOMS OVER A PERIOD OF 14 DAYS RELIABLY PREDICT ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS (UC)
24. Tu1875 IMPACT OF DISEASE DURATION ON TOFACITINIB EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS
25. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY
26. Su1921 THE ESCALATION OF THERAPY OR INTERVENTION (ETI) CALCULATOR FOR ULCERATIVE COLITIS - DOES IT HAVE THE POTENTIAL TO HELP OUTPATIENT CAPACITY MEET DEMAND?
27. Su1938 PATIENT REPORTED OUTCOMES: THE ICHOM STANDARD SET FOR IBD IN REAL LIFE PRACTICE HELPS QUANTIFY DEFICITS IN CURRENT CARE
28. Su1925 EARLY PREDICTION OF OUTCOME IN ACUTE SEVERE ULCERATIVE COLITIS (ASC) - COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES AT PRESENTATION, WITH DAY 3 CRITERIA
29. Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data
30. Mo1891 – Post-Marketing Safety Experience of Vedolizumab in Patients Receiving Concomitant Treatment with Other Biologics
31. Sa1801 – Emerging IBD Demographics in South Asia and Middle East : A Pilot Study from the IBD Emerging Nations' Consortium (IBDENC)
32. Tu1721 – Maintenance of Efficacy Following Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission
33. Tu1792 – Gut Microbiome Diversity in Acute Severe Colitis is Distinct from Mild to Moderate Ulcerative Colitis
34. Tu1714 – Impact of Upadacitinib on the General Clinical Condition of Patients with Crohn's Disease (CD): Data from the Randomised Celest Study
35. Mo1878 – Lymphocyte Activation Gene (LAG)-3 on T Cells is a Potential Therapeutic Target in Ulcerative Colitis
36. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm
37. Su1795 - Developing an Index that Predicts Escalation of Therapy at an Outpatient Appointment in Patients with Known Ulcerative Colitis (UC)
38. 1003 - New Faecal Calprotectin Cut-Off Points for Remission and Active Disease Defined by Uceis and Nancy Indices in Ulcerative Colitis
39. Sa1775 - A Novel Phase 1 Trial Design to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Top1288, a Narrow Spectrum Kinase Inhibitor, Delivered Topically to the Colon via Oral Administration
40. Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm
41. Sa1703 - Post-Marketing Safety Experience of Vedolizumab in Older Patients with Inflammatory Bowel Disease
42. Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
43. Correlation between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices
44. Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm
45. Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections
46. Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada
47. Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience
48. Treat to Target: Recommendations in Ulcerative Colitis (UC) in Practice: Clinician Perceptions and Potential Barriers
49. Zero Diagnostic Yield of Dysplasia in Polyp Adjacent Biopsies for Patients with Inflammatory Bowel Disease
50. Predictors of Long-Term Outcomes in Patients with Acute Severe Ulcerative Colitis: A Northern Indian Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.